Biotechnology

Phyto Extractions Inc. Announces Proposed Acquisition of PerceiveMD, a Multidisciplinary Centre for Medical Cannabis and Psychedelic Therapies

August 11, 2021 4:15 PM

LANGLEY, BC / ACCESSWIRE / August 11, 2021 / Phyto Extractions Inc. (formerly, Adastra Labs Holdings Ltd.) (CSE:XTRX)(FRA:D2EP) (“Phyto Extractions™” or the “Company”) is pleased to announce that it has entered into a share purchase agreement dated August 10, 2021 (the “Share Purchase Agreement”) pursuant to which the Company has agreed to acquire, indirectly through its wholly-owned subsidiary Adastra Labs Inc. (“Adastra”), all the issued and...

Read more

Applied UV Continues Successful Installation of Airocide(R) Systems at Multiple Wineries in Europe

August 10, 2021 9:40 AM

Hungary's leading wine technology company, Cellarius, has recently installed additional Airocide® units to help wineries remain open and protect staff, visitors, and winemaking operations MOUNT VERNON, NY / ACCESSWIRE / August 10, 2021 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), an infection control technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic...

Read more

BioLargo Q2 2021 Earnings Results Webcast and Conference Call Wednesday, August 17, 2021 - 11:00 AM Eastern Time

August 10, 2021 7:15 AM

WESTMINSTER, CA / ACCESSWIRE / August 10, 2021 / BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and full-service environmental engineering company, will host an investor webcast and conference call on Wednesday August 17, 2021, at 8:00 am PST / 11:00 am EST, open to the public, to review the company's financial results, discuss recent events, and conduct a question-and-answer session. The webcast, accompanying presentation...

Read more

Applied UV to Host Second Quarter 2021 Conference Call on August 17th

August 9, 2021 4:30 PM

MOUNT VERNON, NY / ACCESSWIRE / August 9, 2021 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), an infection control technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, announced that the Company will be hosting an investor conference call and live webcast on...

Read more

EV Biologics NFT Dividend Information

August 9, 2021 9:00 AM

NASHVILLE, TN / ACCESSWIRE / August 9, 2021 / EV Biologics Corp, OTC PINK:YECO, today updated shareholders with further details about its NFT Warrant Dividend. Attached is a preliminary image from the 3D animation still under development that will be issued as an NFT dividend Daniel Mckinney CEO said: "this NFT will capture the stunning visual quality inherent in many biological systems, as in this artistic rendering of a fluorescent micrograph...

Read more

Wuhan General Group Updates on Third Scientific Paper Published on Psychedelics

August 5, 2021 9:25 AM

CAPE TOWN, SA / ACCESSWIRE / August 5, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research, is pleased to announce the following corporate update: The research team funded by Wuhan General Group has successfully published a third paper on psychedelic science. The paper entitled "Anti-Inflammatory Effects of Four...

Read more

Hillstream BioPharma and Minotaur Therapeutics Sign Term Sheet to Advance Next-Generation Targeted Knob Biologics for Undruggable Targets

August 5, 2021 8:30 AM

Development partnership expected to capitalize upon tumor targeting Quatramers and novel "Knob" biologics Knob biologics with ultra-long CDRs could be effective against undruggable targets BRIDGEWATER, NJ / ACCESSWIRE / August 5, 2021 / Hillstream BioPharma, Inc. ("Hillstream", the "Company") today announced the signing of a non-binding term sheet with Minotaur Therapeutics ("Minotaur") to advance the development of the next generation targeted...

Read more

Pressure BioSciences Unveils Aggressive Growth Plan and Goals for Second Half 2021; Company Marches Toward UST Commercial Release, Up-listing, and Profitability

August 5, 2021 7:31 AM

Company's Strong First Half 2021 Viewed as Launch Pad for Accelerating Second Half and Growth Trajectory, Propelled by Multiple Platform Technologies Building Market Traction SOUTH EASTON, MA / ACCESSWIRE / August 5, 2021 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide...

Read more

ITOCO welcomes Mr. Xavier Eyamba as Director of its African Management and Development Team, Carbon Credits

August 4, 2021 8:00 AM

TORONTO, ON / ACCESSWIRE / August 4, 2021 / ITOCO INC. (OTC PINK:ITMC) is pleased to announce that Mr. Xavier Eyamba has joined the firm as Director of its African Management and Development Team, Carbon Credits and Capture. Mr. Eyamba has over 25 years of experience supporting cross-functional teams for results-driven cutting-edge technology solutions to address the Environment, Greenhouse-gas emissions reduction across the Agriculture,...

Read more

Pieris Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update

August 4, 2021 7:00 AM

COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON WEDNESDAY, AUGUST 4, 2021 AT 8:00 AM EDT Announced inhaled program PRS-220 for the treatment of IPF and was selected to receive a Bavarian government grant of approximately $17 million to evaluate the program for post-COVID pulmonary fibrosis Signed respiratory and ophthalmology agreement with Genentech with a $20 million upfront payment and more than $1.4 billion in potential additional milestone...

Read more

Apollo Endosurgery, Inc. Reports Record Endoscopy Revenue in Second Quarter, Raises Full-Year Outlook Conference Call to Discuss Results Today at 3:30 p.m. CT / 4:30 p.m. ET

August 3, 2021 4:01 PM

AUSTIN, TX / ACCESSWIRE / August 3, 2021 / Apollo Endosurgery, Inc. ("Apollo") (Nasdaq:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced financial results for the second quarter ended June 30, 2021. Highlights Achieved total revenue of $16.6 million, an increase of 194% compared to the second quarter of 2020, and a new revenue record for the Company* Increased Endoscopic...

Read more

FDA Grants Breakthrough Device Designation Status for Hancock Jaffe's VenoValve

August 3, 2021 8:05 AM

- Goal of FDA Breakthrough Device Program is to speed up development by giving priority to devices that treat life-threatening or irreversibly debilitating conditions - Company preparing to begin SAVVE U.S. pivotal trial for VenoValve - VenoValve is a potential treatment for approximately 2.4 million U.S. patients that suffer from severe Chronic Venous Insufficiency in the deep veins of their legs IRVINE, CA / ACCESSWIRE / August 3, 2021 /...

Read more

Pieris Pharmaceuticals Strengthens Executive R&D Leadership Team

August 3, 2021 8:00 AM

Tim Demuth, M.D., Ph.D., joins Pieris as Chief Medical Officer Shane Olwill, Ph.D., promoted to Chief Development Officer BOSTON, MA / ACCESSWIRE / August 3, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced the appointment of Tim Demuth, M.D.,...

Read more

EV Biologics NFT Dividend Warrant Date

July 30, 2021 9:00 AM

NASHVILLE, TN / ACCESSWIRE / July 30, 2021 / EV Biologics Corp., OTC PINK:YECO, today confirmed for share holders its NFT Warrant Dividend shareholders-of-record date. YECO's shareholders-of-record on July 30, 2021 will receive the Warrant. The Company advises shareholders to be certain to hold their shares for at least several days thereafter to ensure their name is on the DTC list. Shareholders possessing less than 100 shares will not be...

Read more

Dyadic to Report Second Quarter 2021 Financial Results

July 29, 2021 4:30 PM

JUPITER, FL / ACCESSWIRE / July 29, 2021 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it will report its...

Read more

ReShape Lifesciences to Report Second Quarter 2021 Financial and Operational Results on Thursday, August 5, 2021

July 29, 2021 8:30 AM

Webinar will be available discussing recent major milestones that same day SAN CLEMENTE, CA / ACCESSWIRE / July 29, 2021 / ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the Company is scheduled to release its second quarter financial results on Thursday, August 5, 2021, before the financial markets open. "We look forward to announcing our significant...

Read more

Applied UV, Inc. Announces Full Exercise of Over-Allotment Option

July 29, 2021 8:00 AM

MOUNT VERNON, NY / ACCESSWIRE / July 29, 2021 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), an infection prevention technology company that applies the power of narrow-range ultra violet light ("UVC") to destroy pathogens safely, thoroughly, and automatically, today announced the that the underwriters of its 10.5% Series A Cumulative Perpetual Preferred Stock (the "Series A Preferred Stock") have exercised in full their...

Read more

Enzolytics Reports Its Progress Toward Completion Of Clinical Trials for Its ITV-1 ANTI-HIV Therapeutic and Securing Use Authorization Under the European Medicines Agency

July 29, 2021 7:30 AM

COLLEGE STATION, TX / ACCESSWIRE / July 29, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) (http://enzolytics.com/) has completed arrangements and agreements with Danhson (https://danhson.bg/en/) and Clinic Design (https://clinicdesign.eu/) to advance its anti-HIV therapeutic ITV-1 to production and clinical trials. These steps are prefatory to approval by the European Medicines Agency (EMA), leading to patient use authorization. Production of the...

Read more

Lexaria's DehydraTECH-CBD Lowers Blood Pressure

July 29, 2021 7:05 AM

Human Clinical Study HYPER-H21-1 evidences a rapid and sustained drop in blood pressure with DehydraTECH-CBD and excellent tolerability KELOWNA, BC / ACCESSWIRE / July 29, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is extremely pleased to issue partial results from human clinical study HYPER-H21-1 evaluating DehydraTECHTM-processed cannabidiol ("CBD")...

Read more

Xenetic Biosciences, Inc. Announces Closing of $12.5 Million Private Placement Priced at a Premium to Market

July 28, 2021 2:00 PM

FRAMINGHAM, MA / ACCESSWIRE / July 28, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, today announced the closing of its previously announced private placement with a single healthcare-focused institutional investor for 4,629,630 shares of its common stock...

Read more